XRAY — Stock Film
STOCK FILMSCENE 1/11XRAY · $13.46
Stock Expert AI presents
XRAY
DENTSPLY SIRONA Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
DENTSPLY SIRONA Inc. A quick introduction.

On the stock market since 1987, it operates in the world of health and science. It has 14,000 employees. Now — the numbers.

on the stock market since 1987
14K employees
$2.7B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.2.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

WHERE DOES THE MONEY COME FROM?
59%Technologies and Equipment
Technologies and Equipment 59%Consumables 41%
59% of all revenue comes from a single line: Technologies and Equipment.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

In the vault right now:
$0
DEBT: $2.5B
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
69
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
58
average

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
76
strong

Clearly above the class average — a step short of the very top.

GROWTH
47
weak

Clearly below the class average.

PRICE MOMENTUM
60
average

The price is looking for direction — no strong breakout, no collapse.

WORTH WATCHING

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking8/10
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
Little set aside for the future2/10
The stock has lost its spark3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 91 buys and 17 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.64 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/2
The losses continue

A loss of $598M against $3.7B in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, XRAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: XRAY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film